Get Live Data

Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. SLN.L Share Price
  4. SLN.L Share Regulatory News
  5. Proposed Placing

Pin to quick picksSLN.L Regulatory News (SLN)

SLN.L Information
  • There is currently no data for SLN

Proposed Placing

21 Nov 2012 07:00

RNS Number : 6362R
Silence Therapeutics PLC
21 November 2012
 



 

 

 

 

 

Proposed Placing

 

 

London, 21 November, 2012 - Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), announces that the Company is in advanced discussions to raise additional funds from a strategic partner and existing shareholders through the issue of new ordinary shares.

 

The proposed issue of new ordinary shares is not expected to require shareholder approval.

 

Further details will be announced in due course.

 

-Ends-

 

Silence Therapeutics

Ali Mortazavi (+44 7768 694739 /Tim Freeborn (+44 20 7491 6520)

Email: a.mortazavi@silence-therapeutics.com

t.freeborn@silence-therapeutics.com

 

N+1 Singer

Shaun Dobson/Jennifer Wyllie

+44 20 7496 3000

shaun.dobson@n1singer.com

jenny.wyllie@n1singer.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDBBDBDDDBGDG
12345678910
Date   Source Headline
17th Feb 20217:00 amRNSFirst dosing for SLN360
15th Feb 20213:55 pmRNSHolding(s) in Company
15th Feb 20211:14 pmRNSHolding(s) in Company
12th Feb 20214:57 pmRNSHolding(s) in Company
12th Feb 20214:53 pmRNSHolding(s) in Company
12th Feb 202112:10 pmRNSAdditional Listing and Total Voting Rights
11th Feb 20215:29 pmRNSHolding(s) in Company
11th Feb 202111:06 amRNSHolding(s) in Company
8th Feb 20214:28 pmRNSAdditional listing and Total Voting Rights
5th Feb 20217:00 amRNSSilence Announces $45m Private Placement
29th Jan 20212:35 pmRNSAdditional listing and Total Voting Rights
25th Jan 202112:41 pmRNSAdditional listing and Total Voting Rights
7th Jan 20217:00 amRNSHoldings in Company
6th Jan 202111:08 amRNSGrant of Options
6th Jan 202110:08 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSSilence Therapeutics Appoints Craig Tooman as CFO
6th Jan 20217:00 amRNSBoard of Directors Appointment
5th Jan 20217:00 amRNSJanuary Conference Schedule
4th Jan 202111:45 amRNSHoldings in Company
15th Dec 202012:28 pmRNSHolding(s) in Company
4th Dec 20205:08 pmRNSAdditional listing and Total Voting Rights
3rd Dec 20209:45 amRNSDirector/PDMR Shareholding
3rd Dec 20209:44 amRNSDirector/PDMR Shareholding
17th Nov 20203:44 pmRNSAdditional listing and Total Voting Rights
16th Nov 20207:00 amRNSPositive pre-clinical data presented
2nd Nov 20207:00 amRNSSilence Therapeutics Appoints Dr. Marie Wikström
29th Oct 20204:41 pmRNSSecond Price Monitoring Extn
29th Oct 20204:36 pmRNSPrice Monitoring Extension
16th Oct 20202:05 pmRNSDirector/PDMR Shareholding
14th Oct 20201:15 pmRNSAdditional listing and Total Voting Rights
12th Oct 20203:49 pmRNSDirector/PDMR Shareholding
8th Oct 20207:00 amRNSChange to Executive Leadership Team
6th Oct 20204:25 pmRNSAdditional Listing and Total Voting Rights
1st Oct 20207:00 amRNSConference Participation
23rd Sep 20208:59 amRNSHolding(s) in Company
23rd Sep 20207:06 amRNSSecond Price Monitoring Extn
23rd Sep 20207:04 amRNSPrice Monitoring Extension
22nd Sep 20204:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20207:05 amRNSGrant of options
14th Sep 20207:00 amRNSSilence Therapeutics announces new CEO
14th Sep 20207:00 amRNS2020 interim results
8th Sep 20207:01 amRNSR&D update
8th Sep 20207:00 amRNSInstructions exchanging ordinary shares for ADSs
8th Sep 20207:00 amRNSCompletion of Nasdaq listing
7th Sep 20205:47 pmRNSHolding(s) in Company
4th Sep 20202:18 pmRNSHolding(s) in Company
3rd Sep 20207:00 amRNSSilence to Participate in US Investor Conferences
1st Sep 20207:00 amRNSSilence Therapeutics Notice of Results
21st Aug 20207:00 amRNSSilence Therapeutics Files Registration with SEC
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
JMAT
Johnson Matthey
LSE
-1.62%
BEZ
Beazley
LSE
0.12%
CTY
City Of London Investment
LSE
0.18%
ABC
ABC.L
LSE
0.00%
TCM
TCM.L
LSE
0.00%
Trending
DFDV
Defi Dev Corp
LSE
165.22%
GGP
Greatland Resources
LSE
-1.71%
IMM
Immupharma
LSE
4.84%
NTVO
Nativo Resources
LSE
-13.46%
KOD
Kodal Minerals
LSE
0.00%